Medical/Pharmaceuticals

Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS) that Demonstrate Elacestrant's PFS Increases with Duration of Prior CDK4/6i in ER+, HER2- in Metastatic Setting

* Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors * Elacestrant side effects were manageable and consistent with previously reported result...

2022-12-01 00:56 1766

Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index

LONDON and HONG KONG, Nov. 30, 2022 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced that its board of directors has authorized a share repurchase program, and that it has been included as a c...

2022-11-30 22:15 2898

Kira Pharmaceuticals Announces First Cohort of Patients Dosed in Phase 2 Study of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)

CAMBRIDGE, Mass., Nov. 30, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced that the first cohort has been dosed in a Phase 2 trial evaluating KP104 for the treatment of pa...

2022-11-30 20:00 1482

Cardiac Troponin Diagnostics Market Growth Boosted by High-sensitivity Point-of-care Testing

The rise in emergency department visits due to cardiac complaints drives the demand for cTn biomarkers SAN ANTONIO, Nov. 30, 2022 /PRNewswire/ -- The global demand for cardiac troponin (cTn) diagnostics biomarkers is increasing as more patients with cardiac complaints are visiting emergency depa...

2022-11-30 16:12 1224

Global alliance of heart patient organizations unveils new Global Cholesterol Action Plan to prioritize unhealthy cholesterol as a main public health issue

GALWAY, Ireland, Nov. 30, 2022 /PRNewswire/ -- The Global Heart Hub has today launched its Global Cholesterol Action Plan  to reduce the impact of unhealthy cholesterol levels . Presented at their annual UNITE Summit , the Action Plan follows and bu...

2022-11-30 16:00 1610

First Patient dosed in a Head-to-Head First-Line Bridging Study of HANSIZHUANG for ES-SCLC treatment in the US

SHANGHAI, Nov. 30, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient was dosed in NCT05468489, a bridging head-to-head trial inthe United States comparing HANSIZHUANG (serplulimab), an innovative anti-PD-1 monoclonal antibody (mAb) independently develo...

2022-11-30 08:00 2630

Digital Technologies Driving Transformational Growth Across the Biomanufacturing Value Chain

Digitalization enables a sustainable, effective, cost-efficient, and error-free system for biomanufacturing SAN ANTONIO, Nov. 30, 2022 /PRNewswire/ -- The biomanufacturing sector is experiencing a digitalization transformation that is aligned with Industry 4.0. According to Frost & Sullivan's re...

2022-11-30 02:15 2814

Etiometry Applauded by Frost & Sullivan for Enabling Timely Decision Support for Critical Care with Its Digital and Automated Solution

The Etiometry Platform elevates clinical staff performance and identifies areas requiring urgent attention for better clinical outcomes, shorter hospital stays, and enhanced revenue opportunities. SAN ANTONIO, Nov. 29, 2022 /PRNewswire/ -- Frost & Sullivan recently assessed the US clinical decis...

2022-11-29 21:00 2147

A bispecific antibody molecule jointly developed by Buchang Pharmaceutical and REMD Biotherapeutics, partners of GenScript ProBio, received IND clearance from NMPA for clinical trial

NANJING, China, Nov. 29, 2022 /PRNewswire/ -- Buchang Biopharmaceutical and REMD Biotherapeutics, partners of GenScript ProBio, recently received IND approval of BC008-1A from China NMPA for Phase 1 clinical trial. BC008-1A (NMPAIND number: CXSL2200315), a bispecific antibody drug co-targeting th...

2022-11-29 21:00 2025

TargEDys and SymbioPharm enter an exclusive partnership to launch SymbioLife® Satylia® in Germany

PARIS, Nov. 29, 2022 /PRNewswire/ -- TargEDys and SymbioPharm signed an exclusive marketing and distribution agreement for the launch of SymbioLife® Satylia® inGermany. The novel dietary supplement based on the next-generation probioticHafnia alvei HA4597 will be available from January 2023. Sym...

2022-11-29 18:15 2358

Probiotic strain SNZ 1969® helps manage IBS-D & IBS-C symptoms effectively, latest clinical study shows

HYDERABAD, India, Nov. 29, 2022 /PRNewswire/ -- Latest study shows Sanzyme Biologics'sBacillus coagulans SNZ 1969® (Weizmannia coagulans SNZ 1969), a natural spore forming probiotic strain over five decades of use and more than 30 human studies across age groups found to be effective in managing ...

2022-11-29 15:44 2436

BGI Genomics, Naleya Genomics Indonesia, MGI, and Bumame contribute aid packages to Cianjur earthquake relief efforts

CIANJUR, Indonesia, Nov. 29, 2022 /PRNewswire/ -- A 5.6-magnitude earthquake struck the Cianjur district,West Java last Monday (Nov. 21, 2022). As part of earthquake relief efforts, BGI Genomics, its subsidiary Naleya Genomics Indonesia (NGI) and MGI are partnering withIndonesia's leading healthc...

2022-11-29 08:38 2655

Ascletis Announces IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Accepted by China NMPA

HANGZHOU, China and SHAOXING, China, Nov. 29, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that the Investigational New Drug (IND) application of ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease (3CLpro) for COVID-19, has been ac...

2022-11-29 08:10 3512

OPEN Health Appoints David P. King as Non-Executive Chairman and Paul Carter as Independent Board Member

LONDON, Nov. 28, 2022 /PRNewswire/ -- OPEN Health, a leading global provider of scientific communication and market access services helping pharmaceutical companies to unlock the full potential of their clinical and commercial assets, majority owned by Astorg, has announced additions to its board...

2022-11-28 17:00 2444

COLOTECT - Non-invasive Colorectal Cancer Screening Test has been launched in Southeast Asia

BANGKOK, Nov. 28, 2022 /PRNewswire/ -- COLOTECT is a non-invasive colorectal cancer (CRC) self-sampling test that can detect the methylation status of exfoliated cell genes in the intestine, help screen for colorectal cancer and precancerous lesions risk, and detect bowel cancer risk even in the ...

2022-11-28 16:08 2243

TELEHEALTH USAGE IN ASIA PACIFIC FOR PEOPLE LIVING WITH HIV INCREASING, BUT DATA PRIVACY AND LACK OF PERSONAL CONTACT STILL SEEN AS A BARRIER TO WIDER USE

- Half of the people living with HIV (PLHIV) and individuals at-risk (IARs) surveyed in the region increased their usage of telehealth services over the past year; this is driven by the availability of new telehealth services during pandemic - Top factor impacting usage of telehealth services fo...

2022-11-28 15:00 2679

Nuance Pharma announces partnership with DKSH to launch Bentrio™ Nasal Spray in Hong Kong and Macau

SHANGHAI, Nov. 28, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces partnership with DKSH Hong Kong (DKSH HK) Business Unit Healthcare to launch BentrioTM nasal spray in Hong Kong and Macau, marking the very first milestone of Nuance Pharma's commercial expansion in the APAC market. U...

2022-11-28 13:40 4316

Peptron's PT105, a sustained-release Leuprolide, established the bioequivalence with Takeda's Leuplin

* Peptron's PT105, a sustained-release Leuprolide, established the bioequivalence with Takeda's Leuplin.  * Global and regional deal to be initiated. * PT105 represents Korea's first commercialized generic drug of Leuplin, applied with SmartDepot technology. * Development of 3- and 6-month...

2022-11-28 09:00 2837

Everest Medicines Announces Major Regulatory Updates in Taiwan and South Korea for Nefecon for the Treatment of Primary IgA Nephropathy

-- Taiwan Food and Drug Administration grants Accelerated Approval Designation (AAD) to Nefecon -- -- Ministry of Food and Drug Safety in South Korea grants ODD to Nefecon -- -- Nefecon is a first-in-disease treatment for IgAN patients and has been approved in U.S. and E.U. -- SHANGHAI, Nov. 28...

2022-11-28 08:27 3240

Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings

ROCKVILLE, Md. and SUZHOU, China, Nov. 28, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...

2022-11-28 08:00 3917
1 ... 105106107108109110111 ... 382